Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use LACOSAMIDE TABLETS safely and effectively. See full prescribing information for LACOSAMIDE TABLETS Additional pediatric use information is approved for UCB, Inc.’s VIMPAT® (lacosamide) tablets and oral solution. However, due to UCB, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.. LACOSAMIDE tablets, film coated tablet, for oral use, CV Initial U.S. Approval: 2008
Medication labelWhy this: Advisory · dailymed-prescription
Lacosamide is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. Lacosamide is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older. Additional pediatric use information is approved for UCB, Inc.’s VIMPAT ®(lacosamide) tablets and oral solution. However, due to UCB, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.
- generic_name
- lacosamide
- product_names
- LACOSAMIDE
- ndc
- 50228-192, 50228-193, 50228-194, 50228-195, 50228-192-30, 50228-192-60, 50228-192-10, 50228-193-30, 50228-193-60, 50228-193-10, 50228-194-30, 50228-194-60, 50228-194-10, 50228-195-30, 50228-195-60, 50228-195-10
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en